A case of autoimmune hepatitis associated with the PCSK9 inhibitor alirocumab.

IF 2.1 4区医学 Q3 MEDICAL LABORATORY TECHNOLOGY

Annals of Clinical Biochemistry Pub Date : 2024-08-04 DOI:10.1177/00045632241269657

Amira Ibrahim, Geeta Prasad, Eric S Kilpatrick, Timothy J Morris

引用次数: 0

Abstract

This is a case of a 61-year-old lady who presented to the lipid clinic with possible familial hypercholesterolaemia (Simon Broome Criteria). She was commenced on atorvastatin; however, 4 weeks later, she developed hepatitis, and therefore her atorvastatin was discontinued. Following that, her liver function tests normalized, and she was diagnosed with statin-induced hepatitis. Three years later, she was seen again in the lipid clinic with an uncontrolled lipid profile, and she was commenced on alirocumab, a Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor. A few days later, she developed hepatitis, and subsequently, the alirocumab was discontinued. She underwent a liver biopsy, which confirmed that she had Autoimmune Hepatitis (AIH) with presumed superimposed drug injury. This is the first reported case of autoimmune hepatitis associated with alirocumab.

查看原文本刊更多论文

一例与 PCSK9 抑制剂 alirocumab 相关的自身免疫性肝炎"。

这是一个 61 岁女士的病例，她因可能患有家族性高胆固醇血症（西蒙-布鲁姆标准）而到血脂诊所就诊。她开始服用阿托伐他汀，但 4 周后出现肝炎，因此阿托伐他汀被停用。此后，她的肝功能检测趋于正常，被诊断为他汀类药物引起的肝炎。三年后，她因血脂控制不佳再次来到血脂门诊就诊，医生让她服用阿利珠单抗，这是一种 9 型蛋白转换酶亚基酶/Kexin（PCSK9）抑制剂。几天后，她患上了肝炎，随后阿利库单抗被停用。她接受了肝脏活组织检查，结果证实她患有自身免疫性肝炎（AIH），并推测有药物损伤叠加。这是首例与阿利珠单抗相关的自身免疫性肝炎病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical Biochemistry Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry

CiteScore

5.20

自引率

4.50%

发文量

期刊介绍： Annals of Clinical Biochemistry is the fully peer reviewed international journal of the Association for Clinical Biochemistry and Laboratory Medicine. Annals of Clinical Biochemistry accepts papers that contribute to knowledge in all fields of laboratory medicine, especially those pertaining to the understanding, diagnosis and treatment of human disease. It publishes papers on clinical biochemistry, clinical audit, metabolic medicine, immunology, genetics, biotechnology, haematology, microbiology, computing and management where they have both biochemical and clinical relevance. Papers describing evaluation or implementation of commercial reagent kits or the performance of new analysers require substantial original information. Unless of exceptional interest and novelty, studies dealing with the redox status in various diseases are not generally considered within the journal''s scope. Studies documenting the association of single nucleotide polymorphisms (SNPs) with particular phenotypes will not normally be considered, given the greater strength of genome wide association studies (GWAS). Research undertaken in non-human animals will not be considered for publication in the Annals. Annals of Clinical Biochemistry is also the official journal of NVKC (de Nederlandse Vereniging voor Klinische Chemie) and JSCC (Japan Society of Clinical Chemistry).